Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
About the Research Project
Program
Award Type
Bold Ideas initiatives
Award Amount
$68,278
Active Dates
July 01, 2022 - June 30, 2024
Grant ID
CA2022001
Goals
This project will identify sex-specific risk profiles associated with Alzheimer’s disease, in order to contribute to the development of sex-specific diagnostic procedures for early detection of dementia and of sex-personalized interventions.
Summary
Our first objective is to determine the risk factors (lifestyle, cardiovascular, psychological) that are associated with pathological hallmarks of AD (neurodegeneration, amyloid, and tau burden) in men and women, separately. For this we will use data from individuals across the AD continuum (from cognitively unimpaired older adults to patients with mild to moderate dementia) and advanced statistical methods, allowing us to relate multiple risk factors to brain alterations. We expect risk profiles to differ between men and women, providing a better characterization of sex differences in AD.
Our second objective is to assess whether these sex-specific risk profiles can predict future cognitive decline and clinical progression. We expect an increased rate of cognitive decline and clinical progression in individuals with higher risk. More specifically, we expect that the risk determined based on sex-specific risk profiles will be more accurate in predicting future decline than a global risk profile, which doesn’t take into account the variability that exists between men and women.
Our third objective is to determine whether the sex-specific risk profiles can be modified by non-pharmacological interventions. More specifically, we will evaluate whether mental training (based either on mediation or foreign language learning) helps modify men and women risk profiles and, in turn, positively impact brain integrity.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD